Conclusions
6.0 Conclusions:

1. Three promising candidate vaccines were developed.
2. Bacterially expressed, recombinant E2 protein was highly immunogenic.
3. BPL inactivated, alum adjuvanted conventional vaccine gave optimum results.
4. Cross-genotypic protection was offered by both recombinant & whole virus-based vaccines.
5. Both vaccine types led to sterilizing immunity in the mouse model.
6. Neutralizing antibodies were long-lasting.
7. These candidates deserve further evaluation and transfer to an industry.